Japan Eyes Oil Futures Intervention to Stabilize Yen Amid Middle East Crisis 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman 
Federal Reserve Hires Robert Hur to Fight DOJ Subpoenas Targeting Jerome Powell 
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Maduro Faces Rare Narcoterrorism Charges in U.S. Court 
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group 
How the war in Iran is already affecting UK farmers and food production 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Iran Allows Oil Tankers Through Strait of Hormuz Amid U.S. Negotiations 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Asian Currencies Hold Steady as Dollar Stays Firm Amid Middle East Uncertainty 
Oil Prices Climb as Iran Reviews U.S. Peace Proposal Amid Middle East Tensions 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
